NCT06165250

A Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C

A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C in Patients With Essential Hypertension and Primary Hypercholesterolemia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 156 (actual)
• Sponsor: Boryung Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical trial is to evaluate the efficacy and safety of co-administrated BR1018B and BR1018C in patients with essential hypertension and primary hypercholesterolemia

Conditions

• Essential Hypertension
• Primary Hypercholesterolemia

Interventions

Type	Name	Description
DRUG	BR1018A	One tablet administered alone
DRUG	BR1018A-1	One tablet administered alone
DRUG	BR1018B	One tablet administered alone
DRUG	BR1018B-1	One tablet administered alone
DRUG	BR1018C	One tablet administered alone
DRUG	BR1018C-1	One tablet administered alone

Timeline

• Start date: 2024-04-17
• Primary completion: 2025-11-11
• Completion: 2025-11-11
• First posted: 2023-12-11
• Last updated: 2025-11-25

Locations

2 sites across 1 country: South Korea